N9289

NVP-231

≥98% (HPLC)

• Synonyme(s) : N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide, adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide
• Formule empirique (notation de Hill): C₂₅H₂₅N₃O₂S
• Numéro CAS: 362003-83-6
• Poids moléculaire : 431.55
• Numéro MDL: MFCD01988824
• Code UNSPSC : 12352200
• ID de substance PubChem : 329818618
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Pureté: ≥98% (HPLC)
• Forme: powder
• Couleur: white to off-white
• Solubilité: DMSO: >10 mg/mL
• Auteur: Novartis
• Température de stockage: 2-8°C
• Chaîne SMILES: O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
• InChI: 1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
• Clé InChI: MVSSJPGNLQPWSW-CIRRPZLZSA-N

Description

Actions biochimiques/physiologiques

Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.

Caractéristiques et avantages

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): nwg
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable